bp-897 and Dyskinesia--Drug-Induced

In monkeys rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), expression of the dopamine D3 receptor was decreased. However, levodopa-induced dyskinesia (LID), similar to the debilitating and pharmacoresistant involuntary movements elicited after long-term treatment with levodopa in patients with Parkinson disease (PD), was associated with overexpression of this receptor. Administration of a D3 receptor-selective partial agonist strongly attenuated levodopa-induced dyskinesia, but left unaffected the therapeutic effect of levodopa. In contrast, attenuation of dyskinesia by D3 receptor antagonists was accompanied by the reappearance of PD-like symptoms. These results indicated that the D3 receptor participated in both dyskinesia and the therapeutic action of levodopa, and that partial agonists may normalize D3 receptor function and correct side effects of levodopa therapy in patients with PD.

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acrylamides; Animals; Antiparkinson Agents; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Haplorhini; Humans; Isoquinolines; Levodopa; Molecular Structure; Motor Activity; MPTP Poisoning; Naphthalenes; Neostriatum; Piperazines; Pyrrolidines; Rats; Receptors, Dopamine D2; Receptors, Dopamine D3

Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Haplorhini; Humans; Parkinson Disease; Piperazines; Receptors, Dopamine

Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Parkinsonian Disorders; Piperazines; Receptors, Dopamine D2; Receptors, Dopamine D3